Edmund Pezalla | Former VP Pharmaceutical Policy and Strategy
Aetna

Edmund Pezalla, Former VP Pharmaceutical Policy and Strategy, Aetna

Edmund J. Pezalla, MD, MPH
Dr. Pezalla in a leading innovator and consultant on payer strategy for pharmaceutical and device manufacturers. He focuses on unlocking the value of new products by developing industry-leading approaches to incorporating payer requirements into development programs, technology assessment plans, and value frameworks. He works with a variety of policy and industry groups on cutting edge coverage policy, innovations in value-based payments, and adaptive regulatory and market entry pathways. He is currently a Scholar-in-Residence at the Duke-Margolis Center for Health Policy in Washington.
 
Dr. Pezalla is the former Vice President for Pharmaceutical Policy and Strategy in the Office of the Chief Medical Officer at Aetna. In this position Dr. Pezalla developed and coordinated strategy for pharmaceutical evaluation and coverage across both the medical and pharmacy benefit, created Aetna’s framework for innovative contracts, and developed Aetna’s public policy positions on drug and device coverage.
 
Dr. Pezalla holds both BS and MD degrees from Georgetown University and an MPH from the University of California at Berkeley. He is a board certified pediatrician and was a Health Services Research Fellow at the University of Michigan.

Appearances:



Pharma Pricing & Market Access USA Day 2 @ 14:50

PANEL: Market access of orphan drugs and the role of multi-criteria decision making

  • Ways for orphan drug manufacturers to improve their ability to compete in competitive markets
  • Advantages of abandoning a (one-size-fits-all) approach
  • The influence of orphan drug biosimilars

back to speakers